TCG Crossover Management, LLC
Sector Allocation
- Healthcare99.8%$4.2B
- Financials0.2%$7.6M
AUM History
13fpro.ai/research/fund/tcg-crossover-management-llc-1839948
Conviction and streaks
Diversifying · top 10 = 57.4%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
ABVX
$800.6MTNGX
$283.9MCGON
$260.8MCOGT
$187.9MIMVT
$171.8MSYRE
$168.7MDNTH
$163.4MMIRM
$124.3MZLAB
$116.6MAMLX
$112.1MGLUE
$111.9MBCRX
$110.2MVOR
$104.4MTYRA
$103.8MDYN
$102.5MIRON
$98.1MRLAY
$80.0MSVRA
$76.2MAURA
$67.7MRVMD
$63.8M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/tcg-crossover-management-llc-1839948
TCG Crossover Management, LLC 13F holdings — Q2 2026
$4.2B portfolio (+19.0% QoQ) · 54 holdings · Q2 2026 13F · top 10 are 57% of the stock portfolio
$800.6M
19.2% of stocks
-7%This quarter-26.9%Since filed10+ qtrsHeld$283.9M
6.8% of stocks
-14%This quarter-10.6%Since filed7 qtrsHeldAIQuality24.7#2,650Est. buyEstimated buy price is Pro: unlock with a free trialTrimmed 2 qtrs in a row$260.8M
6.3% of stocks
No changeThis quarter-16.1%Since filed10+ qtrsHeld$187.9M
4.5% of stocks
-2%This quarter-15.6%Since filed10+ qtrsHeld$171.8M
4.1% of stocks
No changeThis quarter-30.9%Since filed3 qtrsHeld$168.7M
4.1% of stocks
No changeThis quarter-4.4%Since filed4 qtrsHeld$163.4M
3.9% of stocks
No changeThis quarter-31.4%Since filed7 qtrsHeld$124.3M
3.0% of stocks
No changeThis quarter-15.0%Since filed3 qtrsHeld$116.6M
2.8% of stocks
NewThis quarter-9.0%Since filedNew this quarterHeld$112.1M
2.7% of stocks
No changeThis quarter+30.8%Since filed8 qtrsHeld
All holdings — TCG Crossover Management, LLC (Q2 2026)
54 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Monte Rosa Therapeutics, Inc. | Healthcare | $111.9M | 2.7% | 4.62M | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | BIOCRYST PHARMACEUTICALS INC | Healthcare | $110.2M | 2.6% | 11.02M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Vor Biopharma Inc. | Healthcare | $104.4M | 2.5% | 5.67M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Tyra Biosciences, Inc. | Healthcare | $103.8M | 2.5% | 3.25M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | Dyne Therapeutics, Inc. | Healthcare | $102.5M | 2.5% | 4.62M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | Disc Medicine, Inc. | Healthcare | $98.1M | 2.4% | 1.34M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | Relay Therapeutics, Inc. | Healthcare | $80.0M | 1.9% | 4.27M | — | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Savara Inc | Healthcare | $76.2M | 1.8% | 12.36M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Aura Biosciences, Inc. | Healthcare | $67.7M | 1.6% | 9.53M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | Revolution Medicines, Inc. | Healthcare | $63.8M | 1.5% | 341K | -41% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | First Tracks Biotherapeutics, Inc. | Healthcare | $58.3M | 1.4% | 2.90M | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | Kodiak Sciences Inc. | Healthcare | $56.3M | 1.4% | 1.45M | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Avalo Therapeutics, Inc. | Healthcare | $55.8M | 1.3% | 3.02M | +309% | 8 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | LB PHARMACEUTICALS INC | Healthcare | $47.0M | 1.1% | 1.45M | -21% | 4 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | Century Therapeutics, Inc. | Healthcare | $43.4M | 1.0% | 17.75M | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $TECX | Tectonic Therapeutic, Inc. | Healthcare | $41.4M | 1.0% | 1.20M | — | |||
| 27 | $XNCR | Xencor Inc | Healthcare | $39.5M | 0.9% | 2.45M | — | |||
| 28 | $SRZN | Surrozen, Inc./DE | Healthcare | $38.2M | 0.9% | 1.47M | — | |||
| 29 | $EDIT | Editas Medicine, Inc. | Healthcare | $36.0M | 0.9% | 11.11M | New | |||
| 30 | $MBX | MBX Biosciences, Inc. | Healthcare | $35.9M | 0.9% | 650K | — | |||
| 31 | $PHVS | Pharvaris N.V. | Healthcare | $34.9M | 0.8% | 1.01M | New | |||
| 32 | $SLN | Silence Therapeutics plc | Healthcare | $33.3M | 0.8% | 3.03M | — | |||
| 33 | $IFRX | InflaRx N.V. | Healthcare | $32.5M | 0.8% | 14.50M | New | |||
| 34 | $ALT | Altimmune, Inc. | Healthcare | $30.4M | 0.7% | 10.00M | New | |||
| 35 | $JANX | Janux Therapeutics, Inc. | Healthcare | $27.5M | 0.7% | 1.79M | — | |||
| 36 | $CATX | Perspective Therapeutics, Inc. | Healthcare | $27.0M | 0.7% | 7.92M | — | |||
| 37 | $AGMB | AgomAb Therapeutics NV | Healthcare | $26.7M | 0.6% | 2.05M | — | |||
| 38 | $BHVN | Biohaven Ltd. | Healthcare | $26.5M | 0.6% | 1.78M | -62% | |||
| 39 | $AKTS | Aktis Oncology, Inc. | Healthcare | $22.5M | 0.5% | 697K | New | |||
| 40 | $ALEC | Alector, Inc. | Healthcare | $20.1M | 0.5% | 10.00M | — | |||
| 41 | $FBRX | Forte Biosciences, Inc. | Healthcare | $19.6M | 0.5% | 920K | New | |||
| 42 | $MNPR | Monopar Therapeutics | Healthcare | $18.8M | 0.5% | 203K | +54% | |||
| 43 | $OCUL | OCULAR THERAPEUTIX, INC | Healthcare | $16.2M | 0.4% | 1.65M | — | |||
| 44 | $ADCT | ADC Therapeutics SA | Healthcare | $12.2M | 0.3% | 11.39M | — | |||
| 45 | $ALXO | ALX ONCOLOGY HOLDINGS INC | Healthcare | $11.7M | 0.3% | 5.66M | -57% | |||
| 46 | $TRDA | Entrada Therapeutics, Inc. | Healthcare | $7.8M | 0.2% | 1.06M | -54% | |||
| 47 | $CGEM | Cullinan Therapeutics, Inc. | Healthcare | $7.4M | 0.2% | 407K | — | |||
| 48 | $ARVN | ARVINAS, INC. | Healthcare | $5.9M | 0.1% | 707K | -70% | |||
| 49 | $KRRO | Korro Bio, Inc. | Healthcare | $5.5M | 0.1% | 416K | — | |||
| 50 | $RACC | Research Alliance Corp III | Financials | $5.3M | 0.1% | 500K | New | |||
| 51 | $LONA | LeonaBio, Inc. | Healthcare | $4.3M | 0.1% | 464K | — | |||
| 52 | $JATT | JATT II Acquisition Corp. | Financials | $2.3M | 0.1% | 200K | New | |||
| 53 | $CNTX | Context Therapeutics Inc. | Healthcare | $1.5M | 0.0% | 2.68M | — | |||
| 54 | $EIKN | Eikon Therapeutics, Inc. | Healthcare | $495K | 0.0% | 38K | New |
What changed in Q2 2026
Against the previous quarter's 13F: 12 new, 2 added to, 9 trimmed, 7 sold out. Share-count changes; largest moves by dollar size first.
New positions (12)
first bought this quarter
first bought this quarter
$TRAXFirst Tracks Biotherapeutics, Inc.$58.3M
first bought this quarter
$EDITEditas Medicine, Inc.$36.0M
first bought this quarter
$PHVSPharvaris N.V.$34.9M
first bought this quarter
$IFRXInflaRx N.V.$32.5M
first bought this quarter
+6 more in the Excel export
Added to (2)
Trimmed (9)
now $800.6M · held 10+ qtrs, 2 trims in a row
now $283.9M · held 7 qtrs, 2 trims in a row
now $63.8M · held 4 qtrs
$BHVNBiohaven Ltd.-62%
now $26.5M · held 3 qtrs
$ALXOALX ONCOLOGY HOLDINGS INC-57%
now $11.7M · held 2 qtrs
$ARVNARVINAS, INC.-70%
now $5.9M · held 4 qtrs, 2 trims in a row
+3 more in the Excel export
Sold out (7)
$CNTACentessa Pharmaceuticals plcwas $170.3M
held 9+ qtrs
$FULCFulcrum Therapeutics, Inc.was $40.3M
held 7 qtrs
$LQDALiquidia Corpwas $15.2M
held 3 qtrs
$URGNUroGen Pharma Ltd.was $7.3M
held 3 qtrs
$GPCRStructure Therapeutics Inc.was $6.8M
held 9+ qtrs
$UPBUpstream Bio, Inc.was $1.6M
+1 more in the Excel export
Holdings by quarter
Every 13F TCG Crossover Management, LLC has filed, 18 earlier quarters. Pick one to see what it held then.
Is it too late to follow TCG Crossover Management?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 27, 2026.
Average quality of TCG Crossover Management's top 20 holdings: 28/100 (our AI quality score, weighted by position size; 8 of the 20 are scored)
Top 10 since filing
-17.7%
Value-weighted move of the 10 largest stock positions
Turnover
12%
Last quarter; 46% over the last 4
Top 10 weight
57%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
66%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
TCG Crossover Management, LLC disclosed 54 positions worth $4.2B in its Form 13F-HR for Q2 2026, led by $ABVX (Abivax S.A.) at 19.2% of the equity portfolio, followed by $TNGX and $CGON. During the quarter the fund opened 12 new positions and exited 7 — including a new stake in $ZLAB and a full exit from $CNTA. The portfolio is most concentrated in Healthcare (99.8% of disclosed assets). All figures are sourced directly from TCG Crossover Management, LLC’s Form 13F-HR filing with the SEC under CIK 1839948.
Funds like this
managers whose biggest positions overlap TCG Crossover Management'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: TCG Crossover Management, LLC
13F Pro is an AI hedge fund tracker and stock research platform. For TCG Crossover Management, LLC (SEC CIK: 1839948), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in TCG Crossover Management, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.